Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History VTVT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics VTVT

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

vTv Therapeutics Inc

VTVT
Current price
17.50 USD +0.72 USD (+4.29%)
Last closed 16.01 USD
ISIN US9183852048
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 39 441 504 USD
Yield for 12 month -14.59 %
1Y
3Y
5Y
10Y
15Y
VTVT
21.11.2021 - 28.11.2021

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of postprandial hyperglycemia in cystic fibrosis related diabetes patients, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non- central nervous system penetrant PDE4 inhibitor that has completed Phase 1 trials for the treatment of inflammatory diseases. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2"related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress. It has a license agreement Newsoara Biopharma Co., Ltd. o develop and commercialize phosphodiesterase type 4 inhibitors program, including the compound HPP737. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Group LLC. Address: 3980 Premier Drive, High Point, NC, United States, 27265

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

35.50 USD

P/E Ratio

Dividend Yield

Financials VTVT

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures VTVT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+1 017 000 USD

Last Year

+9 000 USD

Current Quarter

Last Quarter

+17 000 USD

Current Year

+928 000 USD

Last Year

-13 595 000 USD

Current Quarter

Last Quarter

-5 000 USD
EBITDA -24 980 000 USD
Operating Margin TTM -147 388.23 %
Price to Earnings
Return On Assets TTM -36.33 %
PEG Ratio
Return On Equity TTM -131.31 %
Wall Street Target Price 35.50 USD
Revenue TTM 17 000 USD
Book Value 1.20 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM -11 690 000 USD
Earnings per share -2.80 USD
Diluted Eps TTM -2.80 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation VTVT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 500.44
Price Sales TTM 2 320.09
Enterprise Value EBITDA -2.11
Price Book MRQ 4.98

Technical Indicators VTVT

For 52 Weeks

12.12 USD 26.99 USD
50 Day MA 18.22 USD
Shares Short Prior Month 18 719
200 Day MA 16.41 USD
Short Ratio 3.88
Shares Short 17 995
Short Percent 1.62 %